New drug combo improves survival in rare, aggressive bone cancer.

2003 MAR 11 - (NewsRx.com & NewsRx.net) -- Adding two experimental drugs to the standard four-drug chemotherapy regimen has significantly improved survival in patients with nonmetastatic Ewing sarcoma, a highly malignant bone cancer of children and young adults, according to a new report.

The large multi-institutional trial led by Holcombe E. Grier, MD, of Dana-Farber Cancer Institute and Children's Hospital Boston, showed that the overall survival rate increased from 61% to 72% for Ewing sarcoma patients with localized disease who underwent the experimental six-drug chemotherapy.

Conducted by members of two large North American pediatric cancer research …